In this double-blind randomized placebo-controlled trial, we hypothesize to observe a reduced incidence of antibiotic associated diarrhae (AAD) in inpatients with a spinal cord injury (SCI) during the intake of probiotics, in comparison to a placebo…
ID
Bron
Aandoening
Spinal cord injury
Dwarslaesie
Faecal incontinence
Diarree
Antibiotics
Antibiotica
Probiotics
Probiotica
Ondersteuning
Reade Center for Rehabilitation and Rheumatology Amsterdam
Winclove Probiotics B.V.
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Incidence of faecal incontinence, defined by frequency, consistency, (un)wanted defecation, measured by the Bristol Stool Scale.
Achtergrond van het onderzoek
Antibiotic-associated diarrhea is a common complication in antibiotic use in patients with a spinal cord injury. Diarrhea primarily leads to feelings of general discomfort and, as as a result, patients might be delayed in their rehabilitation after spinal cord injury. The objective of this study is to investigate whether the use of probiotics can decrease faecal incontinence and positively influence the bowel management regimen in inpatients with a spinal cord injury treated with antibiotics. The use of probiotics will be double-blind controlled with a placebo. The primary outcome that will be compared between the intervention and placebo group is the incidence of faecal incontinence, defined by frequency, consistency, and (un)wanted defecation. Secondary outcome measures are quality of life and nausea.
Doel van het onderzoek
In this double-blind randomized placebo-controlled trial, we hypothesize to observe a reduced incidence of antibiotic associated diarrhae (AAD) in inpatients with a spinal cord injury (SCI) during the intake of probiotics, in comparison to a placebo, when antibiotic treatment is provided.
Onderzoeksopzet
T0 = start of intervention: start use of antibiotics together with probiotics or the placebo
T1 = last day of use of antibiotics (between 5 and 10 days after T0)
T2 = last day of use of probiotics (2 weeks after T1)
T3 = end of follow-up period (2 weeks after T2)
Onderzoeksproduct en/of interventie
Participants will be randomly assigned to receive both an antibiotic treatment and Ecologic® AAD, or an antibiotic treatment and a placebo. Subjects will receive either probiotic or placebo for 26-31 days (depending on the length of antibiotic treatment; 5-10 days); starting together with the antibiotic treatment and ending three weeks after cessation.
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Confirmed diagnosis of SCI
- First admission to a rehabilitation center after the occurrence of SCI.
- Age between 18-75 years
- Requiring treatment with antibiotics
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Known gastro-intestinal diseases
- Abdominal surgery within a year prior to study
- (Previous) radiotherapy or chemotherapy
- Severe auto immune diseases such as SLE and Sjogren
- Patients suffering from severe acute pancreatitis, multiple organ failure (MOF) or sepsis
- Patients receiving enteral feeding with the exception of nasogastric feeding
- Excessive alcohol intake (> 15 consumptions per week)
- (Planned) pregnancy or lactation
- Use of pre-, probiotics in the month before and during the study
- Use of antibiotics in the two weeks before the study
- More than one antibiotic treatment in the 6 month prior to the study.
- Previous participation in this study design
- Duration of antibiotics use longer than 14 days
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL5687 |
NTR-old | NTR5831 |
Ander register | : ABR57438 |